Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal

Kazuyoshi Kaminaka1, Jun-Ichi Matsuda, Chikateru Nozaki

  • 1Applied Research Department, Kikuchi Research Center, The Chemo-sero-therapeutic Research Institute, Kikuchi-city, Kumamoto, Japan.

Viral Immunology
|August 15, 2013
PubMed

Insights

Developing a universal influenza vaccine is possible using the influenza A virus matrix protein 2 ectodomain (M2e) peptide. Adding cysteine residues to the M2e peptide enhanced antibody responses and protection in mice.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • The extracellular domain of matrix protein 2 (M2e) is conserved across all influenza A virus subtypes.
  • M2e represents a potential target antigen for a universal influenza vaccine.

Purpose of the Study:

  • To investigate the impact of incorporating cysteine residues into an M2e peptide.
  • To evaluate the immunogenicity and protective efficacy of modified M2e peptides as universal influenza vaccine candidates.

Main Methods:

  • Synthesized M2e peptides with varying numbers of additional cysteine residues.
  • Immunized mice with these modified peptides, with and without aluminum adjuvant.
  • Assessed antibody titers against M2e and measured protection against lethal influenza virus challenge.

Main Results:

  • Peptides with one to five additional cysteines induced enhanced M2e-specific antibody titers in mice.
  • A peptide with three additional cysteines, combined with an aluminum adjuvant, provided superior protection against lethal influenza challenge compared to the original M2e peptide.
  • These findings suggest M2e peptides with extra cysteines may elicit protective immunity without strong adjuvants.

Conclusions:

  • M2e peptides with additional cysteine residues are promising candidates for universal influenza vaccines.
  • The inclusion of cysteine residues enhances the immunogenic potential of M2e peptides.
  • Further development of M2e-based vaccines could offer broad protection against influenza A viruses.